Antti Johannes Sinisalo

Desentum Oy operates as a research-based biopharmaceutical firm that specializes in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens. The company was founded by Janne Jänis, Marja-Leena Laukkanen, Pekka Allan Antero Mattila, Merja Niemi, Anja Pallas, Juha Rouvinen, and Kristiina Takkinen in 2011 and is headquartered in Espoo, Finland.

VTT Ventures Ltd. invests in its spin-offs with private investors. It provides the entrepreneurs with professional business development support together with its public and private innovation partners to facilitate the spin-off process from business planning to funding. It focuses on extracting value from VTT technology in developing VTT based companies with international growth potential. It offers opportunities in existing startups with high growth potential, stealth mode companies, and through in-house Entrepreneur-in-Residence program. The company was founded on November 6, 2009 and is headquartered in Espoo, Finland.

Zora Biosciences Oy develops biomarker-based diagnostics tests. It focuses on cardiovascular disease. The company's main product is coronary event risk test. Zora Biosciences was founded by Reini Juhani Hurme, Reijo Laaksonen, and Matej Orešic on December 14, 2006 and is headquartered in Espoo, Finland.

Spectral Engines Oy provides industrial automation products. It offers spectral sensors, miniature instruments, spectroscopy, spectrometers, spectral scanners, smart agriculture, portable devices, machine learning and foodscanner. The company was founded by Jarkko Ensio Antila, Uula Kantojärvi and Janne Suhonen in 2014 and is headquartered in Helsinki, Finland.

Plexpress offers high-content gene expression analysis for cell biology research, enabling higher throughput and providing more information than competitors' products. Plexpress analysis service is a cost and time efficient solution for large screens in preclinical drug discovery studies, safety assays and yeast studies. Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company's TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. The principal developers of the technology, Hans Soderlund and Jari Rautio, are still closely involved with the company as Chairman of the Scientific Advisory Board and VP of R&D, respectively. Since starting operations in 2008, the company has carried out projects using the TRAC technology in the fields of pharmaceutical development and academic research.